Form 4: J&J Director Eugene Woods Acquires Deferred Share Units

Johnson & Johnson Director Eugene A. Woods acquired 210.591 Deferred Share Units as part of a cash retainer deferral plan.

Summary

• Eugene A. Woods, a Director at Johnson & Johnson (JNJ), acquired 210.591 Deferred Share Units (DSUs).
• The transaction occurred on September 9, 2025, with each DSU representing the fair market value of one share of Common Stock, which was $178.07 at the time of acquisition.
• These DSUs were obtained as a deferral of a cash retainer under the company's Amended and Restated Deferred Fee Plan for Directors.
• DSUs are to be settled in cash upon the termination of Mr. Woods' directorship.
• Following this acquisition, Mr. Woods beneficially owns a total of 4,841.3962 DSUs, which include accrued dividend equivalent rights.

Sentiment

Score: 7

Explanation: The transaction is a routine, positive signal of director alignment with shareholder interests through equity-linked compensation, but does not indicate significant new strategic developments or financial performance changes.

Positives

• Director Eugene A. Woods increased his beneficial ownership in Johnson & Johnson through the acquisition of 210.591 Deferred Share Units, aligning his interests with long-term shareholder value.
• The acquisition is part of a director compensation plan, indicating a structured approach to executive incentives.
• The DSUs include dividend equivalent rights, ensuring directors benefit from company performance and distributions.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the nature of the Deferred Share Units being settled in cash upon termination of directorship.

Industry Context

This transaction is a routine insider filing for director compensation, common across publicly traded companies. It reflects standard corporate governance practices where non-employee directors often elect to defer cash compensation into equity-linked instruments to align their interests with long-term shareholder value. It does not indicate any specific industry trend or competitive action.

Comparison to Industry Standards

• The deferral of cash retainers into equity-linked instruments like Deferred Share Units is a common practice for non-employee directors in large, established companies across various industries, including healthcare and pharmaceuticals.
• This aligns director incentives with long-term company performance, similar to practices observed at peer companies such as Pfizer (PFE), Merck (MRK), and Abbott Laboratories (ABT), where directors often participate in similar deferred compensation plans.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of director's financial interests with long-term shareholder value through equity-linked compensation.

Next Steps

• The Deferred Share Units will be settled in cash upon the termination of Eugene A. Woods' directorship.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director acquired Deferred Share Units as part of a compensation plan. While it signals continued alignment of management interests with shareholders, it does not provide new material information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. It is a standard disclosure and does not alter the fundamental investment thesis for Johnson & Johnson.

Keywords

Johnson & Johnson, JNJ, Eugene A. Woods, Director, Deferred Share Units, DSU, Insider Transaction, Compensation Plan, SEC Form 4